^
    CANCER:
    Gastrointestinal Cancer
    HER-2 positive
    Gastric Cancer
    pembrolizumab + trastuzumab
    Sensitive
    :
    A1
    FDA - 2d
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab + trastuzumab
    Sensitive
    :
    A1
    FDA - 2d
    IDH1 mutation
    Cholangiocarcinoma
    ivosidenib
    Sensitive
    :
    A2
    Servier Press Release - 2d
    HER-2 positive
    CRC
    fam-trastuzumab deruxtecan-nxki
    Sensitive
    :
    C1
    Lancet Oncol - 3d
    HER-2 positive
    Gastric Cancer
    RC48
    Sensitive
    :
    C3
    Gastric Cancer - 3d
    No biomarker
    CRC
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 1wk
    HER-2 overexpression + PTEN deletion
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab
    Resistant
    :
    C3
    Sci Rep - 1wk
    dMMR/MSI-H + TMB-L
    Pancreatic Cancer
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    dMMR/MSI-H + TMB-L
    Cholangiocarcinoma
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    dMMR/MSI-H + TMB-L
    CRC
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    dMMR/MSI-H + TMB-L
    Gastric Cancer
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    PTEN mutation + MSI-H/dMMR
    Pancreatic Cancer
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    PTEN mutation + MSI-H/dMMR
    Cholangiocarcinoma
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    PTEN mutation + MSI-H/dMMR
    CRC
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    PTEN mutation + MSI-H/dMMR
    Gastric Cancer
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    PTEN mutation + MSI-H/dMMR
    Small Intestinal Carcinoma
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    dMMR/MSI-H + TMB-L
    Small Intestinal Carcinoma
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    HER-2 1899‐1G>A
    Gastric Adenocarcinoma
    trastuzumab
    Resistant
    :
    C4
    The Oncologist - 1wk
    FGFR2b overexpression + HER2 negative
    Gastric Cancer
    FPA-144
    Sensitive
    :
    B
    Amgen Press Release - 2wk
    FGFR2b overexpression + HER2 negative
    Gastroesophageal Junction Adenocarcinoma
    FPA-144
    Sensitive
    :
    B
    Amgen Press Release - 2wk
    MSI-H/dMMR
    Small Intestinal Carcinoma
    pembrolizumab
    Sensitive
    :
    A2
    Clin Cancer Res - 2wk
    BRCA1 S451Lfs*20
    Gallbladder Cancer
    olaparib
    Sensitive
    :
    C4
    Onco Targets Ther - 2wk
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    nivolumab
    Sensitive
    :
    A1
    FDA - 3wk
    No biomarker
    Esophageal Adenocarcinoma
    nivolumab
    Sensitive
    :
    A1
    FDA - 3wk
    No biomarker
    Gastric Cancer
    nivolumab
    Sensitive
    :
    A1
    FDA - 3wk
    KRAS mutation
    CRC
    bevacizumab + PCM-075
    Sensitive
    :
    C2
    Cardiff Oncology Press Release - 3wk
    HER-2 amplification
    Esophageal Adenocarcinoma
    trastuzumab + avelumab
    Sensitive
    :
    C2
    AACR 2021 - 3wk
    HER-2 amplification
    Gastric Adenocarcinoma
    trastuzumab + avelumab
    Sensitive
    :
    C2
    AACR 2021 - 3wk
    MET amplification
    Gastric Adenocarcinoma
    crizotinib
    Sensitive
    :
    C3
    Target Oncol - 3wk
    MET amplification
    GastroEsophageal Cancer
    crizotinib
    Sensitive
    :
    C3
    Target Oncol - 3wk
    KRAS G13D
    CRC
    bevacizumab + PCM-075
    Sensitive
    :
    C3
    Cardiff Oncology Press Release - 3wk
    KRAS G12V
    CRC
    bevacizumab + PCM-075
    Sensitive
    :
    C3
    Cardiff Oncology Press Release - 3wk
    KRAS G12D
    CRC
    bevacizumab + PCM-075
    Sensitive
    :
    C3
    Cardiff Oncology Press Release - 3wk
    ASS1 negative
    HCC
    BCT-100
    Sensitive
    :
    C3
    Invest New Drugs - 3wk
    MSI-H/dMMR + MLH1 deletion + PMS2 deletion
    CRC
    pembrolizumab
    Sensitive
    :
    C4
    Onco Targets Ther - 3wk
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab
    Sensitive
    :
    A1
    No biomarker
    Esophageal Squamous Cell Carcinoma
    nivolumab
    Sensitive
    :
    A1
    No biomarker
    Gastric Adenocarcinoma
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive
    :
    A1
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive
    :
    A1
    HER-2 positive
    Gastric Cancer
    fam-trastuzumab deruxtecan-nxki
    Sensitive
    :
    A1
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    fam-trastuzumab deruxtecan-nxki
    Sensitive
    :
    A1
    BRCA2 mutation
    Pancreatic Cancer
    olaparib
    Sensitive
    :
    A1
    No biomarker
    HCC
    pembrolizumab
    Sensitive
    :
    A1
    No biomarker
    HCC
    bevacizumab + atezolizumab
    Sensitive
    :
    A1
    BRCA1 mutation
    Pancreatic Cancer
    olaparib
    Sensitive
    :
    A1
    MSI-H/dMMR
    CRC
    pembrolizumab
    Sensitive
    :
    A1
    MSI-H/dMMR
    CRC
    nivolumab + ipilimumab
    Sensitive
    :
    A1
    No biomarker
    Gastric Cancer
    TPF
    Sensitive
    :
    A1
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    TPF
    Sensitive
    :
    A1
    PD-L1 expression
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab
    Sensitive
    :
    A1
    BRAF V600E
    CRC
    cetuximab + binimetinib + encorafenib
    Sensitive
    :
    A1
    BRAF V600E
    CRC
    cetuximab + encorafenib
    Sensitive
    :
    A1
    No biomarker
    Colon Cancer
    capecitabine
    Sensitive
    :
    A1
    No biomarker
    Rectal Cancer
    FOLFIRI
    Sensitive
    :
    A1
    No biomarker
    Colon Cancer
    5-fluorouracil + irinotecan
    Sensitive
    :
    A1
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    pembrolizumab
    Sensitive
    :
    A1
    PD-L1 expression
    Gastric Cancer
    pembrolizumab
    Sensitive
    :
    A1
    No biomarker
    CRC
    bevacizumab
    Sensitive
    :
    A1
    HER-2 overexpression
    Gastric Cancer
    trastuzumab
    Sensitive
    :
    A1
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES